Prognostic Factors in Malignant GI Bleeding Treated With Hemostatic Powder

King Chulalongkorn Memorial Hospital

Status: Completed

Conditions: Death

Treatments: Device: Hemostatic powder

Study type: Observational

Funder types: Other

Identifiers

NCT03066700

RP012

Details and patient eligibility

About

This is a retrospective study to identify the prognostic factors of the good outcomes in patients who presented with upper GI bleeding from tumor and received Hemospray via endoscopy for hemostatic control. The good outcomes were assessed by immediate hemostasis, rebleeding at 72 hours as well as 7, 14 and 30 days following presentation at initial bleeding episode and also 6-month survival rate.

Full description

Tumor-related gastrointestinal (GI) bleeding is increasing due to the advancement of treatment in oncology. However, conventional endoscopic hemostatic methods are not reliable to control bleeding. Surgery, embolization, and radiotherapy can served as the salvage hemostasis; though, a bridging endoscopic therapy is required during resuscitation and stabilization of the patients. Hemospray is a recent novel endoscopic hemostatis powder which has a trend to be an effective instrument for controlling the active upper GI tumor bleeding from a match-pair, case-control study by the author's recent publication. Consequently, the authors hypothesized that there are some prognostic factors related to the outcome of Hemospray treatment in tumor bleeding.

Enrollment: 90 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients seen in the emergency room and/or hospitalized for malignant gastrointestinal haemorrhage from 2011 to 2017

Exclusion criteria

• Age < 18 years

Trial design

90 participants in 1 patient group

Hemospray application

Description:

The patients with GI bleeding from tumor and received Hemospray as a hemostasis method.

Treatment:

Device: Hemostatic powder